BRAF and neoplasm: Furthermore, the molecular responses of high versus low grade tumor cells carrying the BRAFV600E mutation to BRAF and MEK inhibition have not been investigated in detail and thus the differential responses in patients with LGG and HGG to these therapies are poorly understood (13).